N onalcoholic fatty liver disease (NAFLD) is highly prevalent among obese and insulinresistant individuals who are also at risk of developing elevated circulating lipids and cardiovascular disease (CVD). (1, 2) Recently, however, a paradoxical increased susceptibility to NAFLD with low circulating lipids was found in carriers of a loss-of-function variant, rs58542926, in the transmembrane 6 superfamily member 2 gene (TM6SF2). (3) (4) (5) Given that dyslipidemia is a major contributor to atherosclerosis and CVD, (6) (7) (8) this
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paradox offers the potential to define mechanisms by which hepatic steatosis can be dissociated from increased CVD risk factors. Understanding the biological function of TM6SF2 may offer critical insight into the etiology of both pathologies.
The TM6SF2 rs58542926 variant is a cytosine-tothymine substitution at coding nucleotide 499, resulting in a glutamate-to-lysine substitution at residue 167 (E167K). While overproduction of apolipoprotein B (ApoB)-containing lipoproteins by the liver and intestine is one hallmark of obesity-associated NAFLD and an independent risk factor of CVD, carriers of TM6SF2 E167K have increased liver lipid stores and unexpectedly lower serum triglyceride (TG), lower low-density lipoprotein-cholesterol (LDL-C), and lower total cholesterol. They also appear protected from CVD despite a higher risk of nonalcoholic steatohepatitis (NASH). (3) (4) (5) (9) (10) (11) (12) (13) TM6SF2 is localized mainly in the endoplasmic reticulum (ER) membrane and predominantly expressed in liver and small intestine, two organs involved in packaging and secretion of dietary lipids in TG-rich lipoproteins (TRLs) and regulation of whole-body lipid homeostasis. (3) Previous mechanistic studies focused primarily on the impact of TM6SF2 loss of function in liver. These reports confirmed the loss-of-function nature of the E167K variant, demonstrating that it results in reduced levels of the protein compared to wild-type TM6SF2 in cultured hepatocytes. (3) Moreover, knockdown of Tm6sf2 in mice with short hairpin RNA (shRNA) increased liver TG content and decreased very low-density lipoprotein (VLDL) secretion, offering a hepatic mechanism underlying the co-occurrence of NAFLD and reduced circulating lipids. (3) The role of intestinal TM6SF2, however, remains unexplored.
The major objective of this study was to investigate whether TM6SF2 may impact intestinal lipid homeostasis similar to its role in liver. Specifically, we tested the hypothesis that TM6SF2 loss of function results in increased lipid accumulation and decreased lipid secretion in the small intestine. Given the association of E167K in humans with NAFLD and progression to NASH, (3, 11, (13) (14) (15) we also characterized potential subcellular mechanisms by which TM6SF2 loss of function contributes to both. We evaluated TM6SF2 loss of function on ER stress due to ER localization of the endogenous protein (5) and the crucial role of ER stress in the development of steatosis and progression to NASH. (16) We performed association studies for lipid traits in the Geisinger Health System (GHS) bariatric surgery and the Amish Complex Disease Research Program (ACDRP) cohorts, followed by in vivo and in vitro mechanistic studies in zebrafish and cultured human enterocytes, respectively. Our findings confirmed the association of E167K with NAFLD and NASH in the GHS cohort and with improved lipid profiles in the GHS and ACDRP cohorts despite wide differences in energy homeostasis status between the two. Upon further examination of the association of circulating lipids with TM6SF2 loss of function in the ACDRP cohort, we found evidence for reduced fasting and postprandial lipemia after a high-fat challenge, suggesting a role for TM6SF2 in regulating intestinal postprandial lipid homeostasis. We then modeled TM6SF2 loss of function in vivo using larval zebrafish, an optically transparent model useful for whole-animal studies of lipid metabolism, (17, 18) and cultured human Caco-2 enterocytes. (19) Our results indicated that loss of TM6SF2 function leads to lipid accumulation in enterocytes, similar to hepatocytes, as well as a similar increase in ER stress in both tissues. Together, these findings suggest that TM6SF2 regulates both hepatic and intestinal lipid and ER homeostasis.
Materials and Methods

STUDY PARTICIPANTS
The TM6SF2 rs58542926 variant was genotyped in 983 bariatric surgery patients in the GHS cohort and 3,556 participants in the ACDRP cohort. Tests of association were carried out for the effect of E167K on serum lipids, liver histology (GHS cohort only), and hepatic fat content by electron-beam computerized tomography (ACDRP cohort only). A high-fat feeding intervention was performed in the ACDRP cohort to evaluate the effect of E167K on fasting and postchallenge lipid traits. (20) Institutional review board approval was obtained from the Geisinger Clinic and University of Maryland, and all subjects provided written informed consent.
ZEBRAFISH EXPERIMENTS
Zebrafish embryos were microinjected with morpholino antisense (control, tm6sf2, or acyl-coenzyme A:diacylglycerol acyltransferase 2 [dgat2]) alone or with human TM6SF2 RNA. Larvae were assessed for morpholino efficacy, gene expression, LDL-C levels, hepatic steatosis by oil red O staining, and ER dilation and cytosolic lipid droplet (CLD) number and size by transmission electron microscopy (TEM) in liver and intestine. Zebrafish care and experimental procedures were carried out in accordance with the Animal Care and Use Committees of the University of Maryland.
CELL CULTURE EXPERIMENTS
Caco-2 cells (ATCC, Manassas, VA) were treated with lentiviral shRNA targeting TM6SF2 and assessed for CLD accumulation by BODIPY staining and confocal imaging analysis. (21) TG synthesis and secretion were determined by [ 3 H]oleic acid pulse-chase experiments (22) and [ 3 H]oleic acid incorporated into TG or secreted into culture media as described. (21) All experimental details and statistical analyses are provided in the online Supporting Information.
Results
ASSOCIATION OF TM6SF2 rs58542926 WITH IMPROVED FASTING AND POSTPRANDIAL LIPID PROFILES IN HUMANS
We first examined the relevance of TM6SF2 function to NAFLD in a large bariatric surgery cohort at the Geisinger Medical Center (Danville, PA; total N 5 983) (Supporting Table S1 ). Individuals with at least one copy of the rs58542926 variant (TM6SF2; c. C>T; p. Glu>Lys; n 5 130) exhibited a higher average steatosis grade of 1.40 6 0.08 versus 1.14 6 0.03 in noncarriers (n 5 853; P 5 0.04; Supporting Table  S2 ). In addition, 43.8% of T-allele carriers exhibited lobular inflammation versus 32.4% carrying the major allele (P 5 0.02; Supporting Table S2 ). Consistent with previous reports, (12, 13) rs58542926 was associated with perivenular fibrosis in 26.6% of carriers versus 17.5% of noncarriers (P 5 0.008; Supporting Table  S2 ). These data suggest that rs58542926 is associated with increased liver steatosis and increased risk for progression to NASH in extreme obesity. Despite the dyslipidemia typically associated with obesity, fasting lipid levels, total cholesterol, TG, and LDL-C were also lower in carriers of the T allele and statistically significant only in the subgroup also exhibiting NAFLD Postprandial lipid responses were calculated as the area under the curve of the TG measurements at fasting and at 1, 2, 3, 4, and 6 hours (P 5 0.05, P 5 0.03, P 5 0.008, P 5 0.04, P 5 0.05, P 5 0.05, respectively). The response relative to the baseline level was determined by calculating the incremental area under the curve of TG. The total area under the curve of TG and postprandial TG levels and the incremental area under the curve were calculated and are shown in the insert with their respective P values. Abbreviations: iAUC, incremental area under the curve; tAUC, total area under the curve.
(P 5 0.02 for total cholesterol and P 5 0.004 for TG; Supporting Tables S1 and S3).
The rs58542926 minor allele frequency (6.7%) in the GHS bariatric surgery cohort translated to a small number of homozygous participants (n 5 3), hindering our ability to assess the impact of carrying two copies of the T allele for this variant. To address this, we analyzed a large founder population cohort from the ACDRP (n 5 3,556), inclusive of nonobese subjects, in which the rs58542926 T allele is significantly enriched (minor allele frequency 5 12%) compared to outbred European populations and thus resulting in a larger number of homozygotes (n 5 51; 1.4%). Association analysis of carriers in the ACDRP cohort revealed the following: (1) no association with body mass index, fasting glucose or insulin, steatosis, or alanine aminotransferase (steatosis: b 5 0.03 6 0.09, P 5 0.68; alanine aminotransferase: b 5 0.005 6 0.016, P 5 0.75); (2) lower alkaline phosphatase (b 5 -0.03 6 0.01, P 5 0.003); (3) lower TG, total cholesterol, and LDL-C (P < 7.1 3 10 -6 , P < 3.6 3 10 -6 , and P < 2.1 3 10 -8 , respectively); and (4) higher high-density lipoprotein cholesterol (P < 5.0 3 10 5 ) (Supporting Tables S4 and S5 ). Lipid subfraction data from a subset of participants (n 5 833) indicated that rs58542926 carriers had lower total non-high-density lipoprotein cholesterol (P 5 2.7 3 10 29 ), VLDL cholesterol (P 5 2.4 3 10 24 ), VLDL 3 cholesterol (P 5 2.2 3 10 24 ), intermediate-density lipoprotein (P 5 1.9 3 10 26 ), real LDL-C (P 5 3.5 3 10 28 ), and remnant lipoprotein cholesterol (P 5 9.8 3 10
26 ) but not high-density lipoprotein or high-density lipoprotein-related subfractions (P > 0.09; Supporting Table S6 ). Lipid profiles of 807 genotyped individuals from the ACDRP cohort who underwent high-fat challenge were available for analysis (20) (Fig. 1 ). T-allele carriers of rs58542926 exhibited lower postprandial triglyceridemia (P < 9.9 3 10 -3 ) with lower total area under the curve (ß 5 -9.5, P < 0.005) and incremental area under the curve (ß 5 -4.25, P < 0.02; Fig. 1 ). Moreover, ApoB48 levels measured at 2 hours postmeal were significantly lower in the rs58542926 T-allele homozygotes (19.1 6 7.5 versus 13.1 6 6.0, values are 6 standard error of mean [SEM], n 5 12, P < 0.02 adjusted for age and sex). This suggests a substantial delay in appearance of ingested lipid into circulating TG and impaired lipid processing by the small intestine. These data therefore prompted us to pursue mechanistic studies in a zebrafish model of TM6SF2 loss of function.
MODELING TM6SF2 LOSS OF FUNCTION IN ZEBRAFISH
The rs58542926 variant is a loss-of-function allele. (3) (4) (5) To model its function, we carried out genetic knockdown in a model organism, the zebrafish, in which hepatic and intestinal lipid homeostasis could be easily observed. We first verified that tm6sf2 was expressed in larval zebrafish liver and gut by whole-mount in situ hybridization and quantitative RT-PCR (Supporting Fig. S1A,B) . Expression continued to be abundant in liver and intestine at adult stages (Supporting Fig. S1C ). We then targeted endogenous expression of the zebrafish ortholog of TM6SF2, tm6sf2, by antisense morpholino oligonucleotide (MO) injected into one-cell embryos. Both splice-blocking MOs, targeting exon 3 (tm6sf2_e3 MO) or exon 4 (tm6sf2_e4 MO), suppressed tm6sf2 expression, with tm6sf2_e4 MO exhibiting more potency at earlier stages and a lack of MO-related off-target effects as detected by no change in p53D113 gene expression, a proapoptotic gene isoform associated with MO off-target effects (Supporting Fig. S2A -C (23) ). We therefore used the tm6sf2_e4 MO to model tm6sf2 loss of function in all subsequent experiments. Suppression of tm6sf2 through this approach increased the proportion of larvae exhibiting visible hepatic lipid (P < 1 3 10 -10 ; Fig. 2B ) versus control MO-injected larvae ( Fig.  2A,B) , correlating with an increased number of CLDs quantified within a 49-nm 2 area of the liver. The average CLD number was 29.9 6 2.3 and 8.9 6 3.6 for exon 4 and control, respectively (values are 6 SEM; n 75; P < 1 3 10 -20 ; Fig. 2B ; Supporting Fig. S3 ). To further validate our model of hepatic steatosis induced by tm6sf2 loss of function in the zebrafish model, we performed CRISPR/Cas9-mediated disruption of the zebrafish tm6sf2 locus by coinjection of larvae with Cas9 mRNA and guide RNA targeting either exon 3 or exon 4. An increase of hepatic steatosis was observed in both CRISPR mutant lines (Supporting Fig. S4A-C) . The mismatch at the genomic locus was confirmed by T7 endonuclease assays and sequencing (24) (Supporting Fig. S4 ).
We quantified LDL-C in tm6sf2-depleted and control MO larvae after dissecting livers and measuring LDL-C in the remaining carcass. (25) With a control diet, carcass LDL-C decreased by tm6sf2 disruption: 0.17 6 0.09 versus 1.90 6 0.19 for tm6sf2_e4 MO and control MO (P < 0.003; Fig. 2C ). Taken together, these data validate the zebrafish model for study of TM6SF2 function and suggest a tm6sf2 role in ApoB-TRL secretion as ApoB-TRL and LDL are directly interrelated.
We next assessed the relevance of rs58542926 to systemic lipid homeostasis in zebrafish by coinjection of tm6sf2_e4 MO with either wild-type human TM6SF2 RNA or E167K RNA. Addition of wild-type TM6SF2 (C) LDL-C levels were quantified after removal of livers from control MO or tm6sf2_e4 MO larvae given a control diet for 48 hours starting at 5 dpf. Data represent average of triplicate values from two pooled groups of 100 larvae each per experiment for two separate experiments. *P < 0.01; ***P 1 3 10 -10 . Abbreviations: CD, control diet; L, liver; SB, swim bladder; WT, wild type.
RNA expression, but not E167K RNA, completely rescued steatosis ( Fig. 2A,B) , supporting the loss-offunction nature of E167K. (3, 5, 13) The average number of ), which was not significantly different from control MO (values are 6 SEM, n 75, nonsignificant).
tm6sf2 DISRUPTION IS ASSOCIATED WITH BOTH ER STRESS AND STEATOSIS
ER stress contributes to hepatic steatosis and progression to NASH. (16) We therefore performed zebrafish studies to evaluate whether loss of tm6sf2 also results in ER stress. TEM examination of liver ultrastructure in unfed larvae at 5 days postfertilization (dpf) (Fig. 3A) revealed an increase in CLDs in hepatocytes with tm6sf2 knockdown versus control MO, consistent with hepatic CLD accumulation observed by whole-mount oil red O staining (Figs. 2A,B and 3A,B). Average CLD area/cell was 1,825 6 238 versus 2,878 6 325 with tm6sf2_e4 MO versus control MO, respectively (P < 0.005; values are 6 SEM, n 5 12 larvae and 31 cells) (Fig. 3B) . Knockdown of tm6sf2, but not control MO, resulted in ER cisternae dilation (Supporting Fig. S6A ,B): cisternae width was 63.7 6 7.3 nm versus 30.0 6 4.4 nm with tm6sf2_e4 MO versus control MO, respectively (P 3 3 10 -64 ; values are 6 SEM, n > 100 ER cisternae). Markers of ER stress, including chop, bip, edem1, and spliced xbp1, examined by quantitative RT-PCR at 5 dpf, were also significantly increased in tm6sf2 morphants versus controls (Fig. 3C) .
Similar results were obtained in human liver biopsies from rs58542926 carriers from the bariatric surgery cohort from the GHS (Danville, PA). We examined the expression of ER stress markers including CHOP, HSPA5, ATF6, ATF4, and spliced XBP1 by quantitative RT-PCR and found a significant increase in carriers of the variant compared to noncarriers with a comparable degree of steatosis (P < 0.05, P < 0.01, P < 0.001, and P < 0.05, respectively). Increased ER was present irrespective of fibrosis (Fig. 3D) .
Together, these observations indicate that steatosis and ER stress are concurrently associated with TM6SF2 loss of function in both zebrafish and human livers ( Fig. 3A-D; Supporting Fig. S6 ), warranting further investigation.
tm6sf2 IS SUFFICIENT TO RESCUE foie gras MUTANT STEATOSIS AND ER STRESS
Given that overexpression of TM6SF2 mRNA reduced the proportion of wild-type larvae exhibiting accumulation of hepatic lipid ( Fig. 2A,B) , its over expression should also ameliorate lipid accumulation in a zebrafish model of NAFLD caused by ER stress. To test this possibility, we examined the foie gras (foigr) zebrafish mutant, which exhibits hepatic steatosis as a result of ER stress. (26, 27) We injected progeny of heterozygous foigr carriers with RNA encoding wild-type TM6SF2. Relative to untreated mutant larvae at 5 dpf, overexpression of TM6SF2 resulted in a significant decrease in the proportion of animals exhibiting oil red O staining in the liver (16% in tm6sf2_e4 MO larvae versus 23% in control MO larvae; Fig. 4A; Supporting Fig. S4) . Expression of the ER stress marker genes chop and edem1 was also significantly reduced in livers of wild-type TM6SF2 RNAinjected larvae, relative to untreated control mutants (Fig. 4B) . In contrast, overexpression of E167K into foigr larvae did not rescue hepatic steatosis as 85% of larvae displayed steatosis and produced an up-regulation of all assessed genes associated with induction of ER stress ( Fig. 4A,B; Supporting Fig. S4 ).
tm6sf2 KNOCKDOWN ENHANCES TUNICAMYCIN-INDUCED ER STRESS GENE EXPRESSION
To further explore the role of tm6sf2 knockdown in ER stress, we examined whether pharmacological induction of ER stress phenocopies the tm6sf2 knockdown ER stress phenotype in zebrafish liver. We used tunicamycin (Tm), an antibiotic that blocks protein Nlinked glycosylation in ER by inhibiting the transfer of Quantitative RT-PCR quantification of ER stress markers from 24 liver biopsies of TM6SF2 Glu167Glu (EE) and TM6SF2 Glu167Lys (EK) carriers. Six EE and EK carriers had been diagnosed with grade 0 or 1 steatosis but no fibrosis, and 6 EE and EK carriers had both steatosis (grade 1 and 2) and fibrosis. Patients were all female and morbidly obese. Results of triplicate assays, n 5 6/group, mean 1 SEM; *P < 0.05, **P < 0.01 for EE versus EE with fibrosis or EE versus EK or EE versus EK with fibrosis; *P < 0.0001. Abbreviation: N, nucleus. GlcNAc to dolichol phosphate and typically causes full activation of most unfolded protein response target genes. (26, 28, 29) To examine the possibility of an epistatic relationship between tm6sf2 and ER stress, we used a combination of tm6sf2 MO and Tm treatment. (30) Combining MO-mediated knockdown of 
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tm6sf2 and Tm treatment enhanced ER stress gene expression (Supporting Fig. S7 ). However, TM6SF2 overexpression did not rescue Tm-induced ER stress (Supporting Fig. S7 ), suggesting that the mechanism by which tm6sf2 deficiency disrupts ER homeostasis likely differs from that underlying Tm-induced ER stress.
REDUCED TG SYNTHESIS AMELIORATES tm6sf2 DEPLETION-INDUCED PHENOTYPES
To determine if tm6sf2-induced ER stress could be alleviated by reduced production of TG, the major ]oleic acid complexed to fatty acid-free bovine serum albumin. Subsequently, during the washout period, the cells were incubated in culture medium containing 5 g fatty acid-free bovine serum albumin per liter of medium for 1 hour. (C) Incorporated radioactivity in TG fraction of cells at the end of the pulse period. Data are mean 6 standard error (n 5 3 independent experiments). (D) Incorporated radioactivity in TG fraction of media at the end of the 1-hour washout, *P < 0.05. Data are mean 6 standard error (n 5 3 independent experiments). (E) Incubation of Caco-2 cells with oleic acid (0.65 mM) for 16 hours caused increased ER stress as evaluated by GRP78, ATF6, ATF4, CHOP, and spliced XBP1 (SXBP1). *P < 0.05, **P < 0.01, ***P < 0.01. Data are mean 6 standard error (n 5 3 independent experiments).
component of hepatic CLD, we examined the consequences of reducing TG production on the steatosis and ER stress phenotypes in zebrafish larvae lacking tm6sf2. We reduced TG formation by inhibiting dgat2, a key enzyme for the final step of TG biosynthesis that is highly expressed in liver. (31) dgat2 MO treatment resulted in effective dgat2 gene knockdown at day 5 ( Supporting Fig. S2 ). Knockdown of dgat2 reduced tm6sf2 knockdown-induced hepatic steatosis, as indicated by oil red O staining, to a level comparable to MO control-treated larvae (Fig. 5A) . Of larvae injected with tm6sf2_e4 MO 89% exhibited liver oil red O staining, a significant increase compared to control MO-treated larvae (25%) or larvae injected with both tm6sf2 and dgat2 (21%; Fig. 5B ). In addition, dgat2 inhibition ameliorated tm6sf2 depletion-induced ER stress. Elevated levels of expression for the ER stress markers chop, bip, and edem1 by tm6sf2 deletion were ameliorated by loss of dgat2 (Fig. 5C ). These findings suggest that inhibition of TG synthesis reduced both hepatic steatosis and ER stress resulting from loss of tm6sf2.
DISRUPTION OF tm6sf2 PERTURBS INTESTINAL CLEARANCE OF DIETARY LIPID
TM6SF2 expression is highest in small intestine in both humans and mice (Supporting Fig. S5A,B) , and delayed postprandial TG excursion was observed in human E167K carriers, suggesting that TM6SF2 has a role in intestinal lipid homeostasis similar to that in liver (Fig. 1) . To test this possibility, we assessed the CLD content of enterocytes in zebrafish at 5 dpf, when larvae begin to rely on dietary lipid, by comparing histology and intestinal CLD in ultrathin-section TEM of larval anterior intestine in three fed states: (1) unfed, (2) immediately after a high-fat meal (3 hour high-fat diet [HFD]), (3) 18 hours after the 3-hour HFD, and (4) 24 hours after the 3-hour HFD. Unfed control larvae did not exhibit CLD accumulation in enterocytes (Fig.  6A ), but the average CLD area per cell surface area was about 30-fold greater in unfed tm6sf2_e4 MO larvae. ER cisternae dilation was also increased (Fig. 6A-D) , consistent with a tm6sf2 role in enterocyte ER and lipid homeostasis in the absence of dietary lipid, similar to its role in liver ( Fig. 3A-C; Supporting Fig. S6A,B) . After a 3-hour HFD, CLDs increased in control larvae and then reduced following 18-hour clearance. The area of CLD relative to cell surface area was 1,059 6 261.21 nm 2 after the 3-hour HFD and then reduced to 96.53 6 52.94 nm 2 after 18-hour clearance (values are 6 SEM, n 5 4-12 larvae, P < 0.01; Fig. 7C ). With tm6sf2 depletion, an increase in CLD was also observed after 3-hour HFD (unfed 781.78 6 388.4 nm 2 versus 3-hour HFD 3,221.4 6 681.62 nm 2 , values are 6 SEM, n 5 12 larvae, P < 0.001 (Figs. 6A and 7A-C) . However, the CLD accumulation observed in tm6sf2-deficient enterocytes after 3-hour HFD was significantly greater than the CLD accumulation in control MO enterocytes (Fig. 7A-D) . Importantly, by 18 hours after a 3-hour HFD, while 90% of the accumulated fat was cleared in enterocytes from zebrafish treated with control MO, only 40% of accumulated fat was cleared in enterocytes from zebrafish treated with tm6sf2 MO. By 24 hours, there was no longer a statistical difference observed among the groups for total CLD area, although tm6sf2-deficient enterocytes still contained a greater number of CLDs compared to control enterocytes (control 4.2 6 0.95 versus tm6sf2 MO 12.9 6 2.6 average CLD/cell; values are 6 SEM, n 5 12 larvae, P < 0.001) (Fig. 7C,D) . Together with our human postprandial lipid measurement, these data support a likely role of TM6SF2 in small intestine lipid clearance.
TM6SF2 MODULATES LIPID CONTENT IN HUMAN CACO-2 ENTEROCYTES AND IS ASSOCIATED WITH ER STRESS
To assess whether our observations in zebrafish could be extrapolated to human cells, we transduced human Caco-2 enterocytes with lentiviral shRNA targeting TM6SF2 (shTM6SF2), resulting in 98% reduction of mRNA versus a scrambled shRNA control treatment (Fig. 8A) . Visualization of intracellular lipid by BODIPY 493/503 staining (21) indicated that TM6SF2 depletion increased intracellular lipid content by 3.7-fold relative to control shRNA treatment (P < 0.01; seven to nine independent experiments; Fig.  8A ,B) in Caco-2 cells incubated with oleic acid (600 lM for 16 hours) but not without exogenous oleic acid (data not shown), suggesting that TM6SF2 depletion increases CLD in enterocytes in response to exogenous lipids. Further, examination of TG synthesis and secretion in enterocytes by pulse-chase studies with [ 3 H]oleate indicated that TM6SF2 depletion did not alter the incorporation of exogenous oleate into intracellular TG, measured after 16 hours, but reduced incorporation into TG secreted into the media after a 1-hour "chase" (P < 0.01; 3-4 independent experiments; Fig. 8C,D) . Finally, we confirmed the ER localization of TM6SF2 in Caco-2 cells; and upon treatment of TM6SF2 shRNA-treated cells with oleic acid (600 lM for 16 hours), we observed significantly increased expression of ER stress markers, including HSPA5, ATF6, ATF4, and CHOP, compared to control (P < 0.001, P < 0.05, P < 0.05, and P < 0.01, respectively; Fig. 8E; Supporting Fig. S4D ). These results corroborate our observations in zebrafish and strongly support a TM6SF2 role in the processing of dietary lipids in human enterocytes.
Discussion
Our findings indicate that TM6SF2 plays a role in both liver and enterocyte lipid homeostasis. Upon depletion of TM6SF2 gene expression in human Caco-2 enterocytes, or its homolog in zebrafish, we observed significant lipid accumulation in response to exogenous lipid in either tissue. These observations are consistent with observations in human carriers of a TM6SF2 loss-of-function variant, who exhibit hepatic steatosis and ER stress progressing to fibrosis and inflammation along with significant decreases in fasting circulating lipids but also reduced postprandial TG excursion. Our findings also reveal that increased ER stress as a result of loss of TM6SF2 expression is concurrent with the observed increased accumulation of CLDs in both human and zebrafish tissues. The rescue of both phenotypes from depletion of TM6SF2 gene expression by simply blocking production of TG and the observation of epistatic interaction with Tm provide strong evidence that the TM6SF2 gene function involves lipid homeostasis, which has a downstream impact on ER stress. Taken together, these findings suggest an important role for TM6SF2 in the mediation of circulating TG through a previously unidentified intestinal function that likely parallels its functions in liver. There is convincing evidence that hypertriglyceridemic states are associated with accelerated atherosclerosis and CVD. (8, 32) Most TG is transported in the plasma by TRLs that are either hepatically derived VLDL or intestinally derived chylomicrons, with considerable overlap of molecular players and pathways involved in processing across the repertoire of TRLs. Our data provide strong support for a role of TM6SF2 in TRL processing, in both liver and intestine.
In fasting conditions, TG is predominantly carried in VLDL particles, whereas in the postprandial state TG is additionally carried in chylomicrons and their remnants. (8) The role of TM6SF2 in modulating VLDL secretion from liver is well documented and has been proposed as the primary mechanism by which fasting lipoprotein profiles are improved in carriers of the loss-of-function variant. (3, 5) Important to its function, ApoB-associated lipoproteins are primarily affected in carriers of the loss-of-function variant, as evidenced by the highly significant effects on LDL-C, VLDL cholesterol, intermediate-density lipoprotein cholesterol, and TG. Our findings offer an additional mechanism by which TM6SF2 depletion may contribute to an improved CVD profile through its role in regulating postprandial intestine-derived TRLs. Our observation that carriers of the T allele have lower postprandial triglyceridemia in response to a high-fat challenge is in agreement with a recent report. (33) Although about 80% of the increase in circulating TG after a fat-load meal comes from ApoB48-containing lipoproteins, (34) approximately 80% of the increase in particle number is accounted for by VLDL particles. (35, 36) ApoB48-and ApoB100-containing particles are cleared from the circulation by common pathways and therefore compete for clearance. (37) Our data support the need for further detailed human kinetic studies to understand the full impact of TM6SF2 in processing of ApoB lipoproteins and the relative contribution of liver and small intestine to the improved lipid profile.
The improved lipid profile in carriers of the E167K variant is in apparent conflict with the variant's adverse effects on NAFLD and progression to NASH. This suggests that impaired TRL secretion may be directly relevant to the retention of intracellular lipid in hepatocytes. Intriguingly, we observed improved lipid profiles in carriers of the variant from two cohorts with vastly different metabolic profiles. The Old Order Amish are a relatively healthy population with less diabetes, more physical activity, and less alcohol consumption than the general population. The variant in TM6SF2 was strongly correlated with reduced circulating lipids in the Old Order Amish, even in the absence of NAFLD or liver dysfunction. (38, 39) In contrast, the variant was associated with increased steatosis, fibrosis, and inflammation in the metabolically stressed conditions found in extremely obese bariatric surgery patients. Similarly, increased association with NASH was reported in obese children carrying the rs58542926 variant. (10) These observations suggest a role for TM6SF2 in both liver and intestinal response but perhaps underscore the role of metabolic stress in unmasking its deleterious effects in liver. Importantly, these findings support the possibility of a common intracellular mechanism by which TM6SF2 functions across tissues.
This suggests that the strength of the association of the TM6SF2 T allele with NAFLD and NAFLD progression may depend on additional factors that compromise hepatic lipid homeostasis. Indeed, our observations of increased association with steatosis, fibrosis, and inflammation in bariatric surgery patients might indicate that extreme obesity is a metabolic stress that impacts the presence of NASH associated with rs58542926. A similarly increased association with NASH was reported in obese children. (10) This may be clinically relevant as it indicates that interventions aiming at either reducing hepatic lipid flux or increasing lipid use may help circumvent the deleterious health consequences of the TM6SF2 variant on liver lipid homeostasis. Overall, our observations in two cohorts with vastly different metabolic profiles support a role for TM6SF2 in both liver and intestinal responses to dietary lipid with improved systemic lipid homeostasis. These data potentially support the possibility of a unifying mechanism at the level of TM6SF2 intracellular function.
Dietary fat absorption is a multistep process that involves temporary storage of dietary fat in CLDs of enterocytes and hepatocytes and repackaging in lipoprotein particles for transport. (40) It is accepted that both CLDs and ApoB-rich lipoproteins originate within the ER bilayer from newly synthesized esterified lipids, but they mature on opposite sides of the bilayer. (40) The current model of chylomicrons and VLDL assembly proposes a two-step process. In the first step newly synthesized ApoB is lipidated during translocation across the ER into the lumen, yielding a primordial particle. In the second step, bulk transfer of core lipids is believed to take place posttranslationally, involving lumenal lipid droplets. (41) Several lines of evidence support a role of TM6SF2 in the packaging and secretion of esterified lipids. Previous reports have indicated that TM6SF2 localizes to the ER in hepatocytes, consistent with our observations in enterocytes. (5) In addition, our zebrafish and cell culture studies indicate that TM6SF2 deficiency reduced the flux of TG toward export in both tissues, and consequently CLD number is increased.
Our data also suggest that it is unlikely that processes upstream of the ER are impaired. It is not likely that fatty acid uptake is impaired given that the introduction of dietary lipid resulted in a significant increase in enterocyte lipid content. The absence of an uptake defect suggests that the localization of a defect is limited to an ER-localized defect in lipid packaging and synthesis or to post-ER trafficking and secretion.
The role of perturbations in the ER in NAFLD has become a subject of considerable interest in recent years. (16) Notably, depletion of tm6sf2 in zebrafish hepatocytes and enterocytes led to both increased CLD accumulation and ER stress in our zebrafish studies. Both of these phenotypes can be successfully rescued simply by dgat2 knockdown, an indication that TG biogenesis and the tm6sf2 loss-associated lipid homeostasis phenotype might be causative of ER stress. Nonetheless, TM6SF2 rescued both steatosis and ER stress in a zebrafish mutant, foigr, where steatosis is thought to be secondary to ER stress. (26) foigr is highly conserved; TRAPPC11 is the human ortholog, but its function remains elusive. Published data suggest that TRAPPC11 functions in the anterograde secretory pathway at an early stage in ER-toGolgi transport. (42) In addition to its trafficking function, recent published data suggest that TRAPPC11 may act upstream of the dolichyl-phosphate N-acetylglucosaminephosphotransferase, the target enzyme responsible for Tm-induced ER stress.
(43) However, results from our epistasis experiments suggest that TM6SF2 overexpression does not rescue Tm-induced ER protein homeostasis, an indication that Tm and tm6sf2 depletion activate ER stress by different mechanisms. If TRAPPC11 deletion causes a backup of VLDL in the smooth ER, (26) our data suggest that TM6SF2 overexpression can compensate for the interrupted trafficking. VLDL and chylomicron precursors are assembled in the ER, and their maturation occurs in the post-ER compartments. (38) However, how this maturation is achieved is only partially understood. Our data support the novel hypothesis that TM6SF2 may be key to the process involved in ApoB lipoprotein maturation.
Further examination of the intracellular mechanisms underlying lipid accumulation will be necessary to fully clarify the function of TM6SF2 in hepatic and intestinal lipid accumulation. The identification of an important role of a single gene in both tissues which are central to the regulation of systemic lipemia offers the exciting possibility of a single gene target to address elevated circulating TRLs from both sources. Further study will also potentially shed light on other interactors that may collaborate with TM6SF2, revealing important insight into the regulation of TRL regulation and secretion. The elucidation of an intestinal role for TM6SF2 offers a first step toward such understanding.
